Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) COO Ryan Cohlhepp sold 12,500 shares of the firm's stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $18.68, for a total transaction of $233,500.00. Following the sale, the chief operating officer directly owned 189,141 shares in the company, valued at approximately $3,533,153.88. The trade was a 6.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Ryan Cohlhepp also recently made the following trade(s):
- On Friday, November 21st, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.05, for a total transaction of $225,625.00.
- On Wednesday, October 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.16, for a total transaction of $227,000.00.
- On Tuesday, October 7th, Ryan Cohlhepp sold 10,900 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.06, for a total value of $196,854.00.
- On Monday, October 6th, Ryan Cohlhepp sold 39,600 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.06, for a total value of $715,176.00.
Bicara Therapeutics Stock Down 1.1%
NASDAQ BCAX opened at $18.15 on Wednesday. The company has a 50-day moving average price of $17.06 and a 200-day moving average price of $13.32. Bicara Therapeutics Inc. has a 52 week low of $7.80 and a 52 week high of $19.75. The firm has a market capitalization of $994.26 million, a P/E ratio of -8.10 and a beta of -0.87.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.12). As a group, equities research analysts anticipate that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.
Wall Street Analyst Weigh In
Several research firms have issued reports on BCAX. Weiss Ratings reissued a "sell (d-)" rating on shares of Bicara Therapeutics in a report on Tuesday, October 14th. Wedbush restated an "outperform" rating and set a $30.00 target price on shares of Bicara Therapeutics in a research note on Monday, November 10th. HC Wainwright cut their price target on Bicara Therapeutics from $41.00 to $40.00 and set a "buy" rating for the company in a research note on Friday, August 22nd. Finally, Wells Fargo & Company boosted their target price on Bicara Therapeutics from $8.00 to $11.00 and gave the stock an "equal weight" rating in a research report on Tuesday, November 11th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Bicara Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $29.67.
Read Our Latest Stock Analysis on BCAX
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the company. Tudor Investment Corp ET AL purchased a new stake in Bicara Therapeutics during the 3rd quarter worth approximately $296,000. Cantor Fitzgerald L. P. purchased a new position in Bicara Therapeutics in the 3rd quarter worth $1,579,000. XTX Topco Ltd increased its holdings in shares of Bicara Therapeutics by 16.5% in the third quarter. XTX Topco Ltd now owns 37,774 shares of the company's stock valued at $596,000 after purchasing an additional 5,360 shares during the period. Vestal Point Capital LP increased its holdings in Bicara Therapeutics by 2.0% in the 3rd quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company's stock worth $80,529,000 after buying an additional 100,000 shares during the period. Finally, Mariner LLC lifted its stake in Bicara Therapeutics by 403.8% during the 3rd quarter. Mariner LLC now owns 62,660 shares of the company's stock valued at $989,000 after acquiring an additional 50,223 shares during the period.
About Bicara Therapeutics
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
